Non-alcoholic Steatohepatitis (NASH)
Conditions
Keywords
Pharmacokinetics, Pharmacodynamics, Obese, PNPLA3 148M Risk Alleles, Multiple Ascending Dose
Brief summary
This study is intended to investigate the safety and tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD2693, following subcutaneous (SC) administration of multiple ascending doses in participants with Non-alcoholic Steatohepatitis (NASH) with fibrosis Stage 0 to 3 and who are carriers of the patatin-like phospholipase domain-containing 3 (PNPLA3) 148M risk alleles.
Detailed description
This study is a double blind, randomised, placebo-controlled, multi-centre study in participants with NASH and fibrosis stage between F0 (no fibrosis) and F3 (bridging fibrosis), and who are carriers of the PNPLA3 148M risk alleles. The study will comprise of: * An optional Pre-Screening Visit may be completed to determine PNPLA3 genotype and collect minimal baseline data and participants who are carriers of the PNPLA3 148M risk allele(s) will continue the study and enter the Screening Period. * A Screening Period with a maximum of 60 days. * For participants in all Cohorts, the dosing period will be 8 weeks during which participants will be resident of the study site for Dose 1 and Dose 3. Dose 1 will have participants reside at the study site from the day prior to study intervention administration (Day -1) until at least 2 days after study intervention administration with discharge on Day 3. Dose 2 will be administered at the study site on Day 29 with no overnight stay. Dose 3 will have participants reside at the study site from the day prior to study intervention administration (Day 56) until at least 2 days after study intervention administration with discharge on Day 59. * Each participant will be followed for approximately 15 weeks post last dose. The study will be performed at up to 30 study sites in the United States (US) and up to 5 study sites in Mexico. Approximately 80 participants comprising of male and female participants of non-childbearing potential may be enrolled into the first 4 cohorts of this study in order to achieve a target of 56 to 64 evaluable participants.
Interventions
DRUGAZD2693
Subcutaneous administration of AZD2693 multiple ascending doses in participants with NASH and who are carriers of the PNPLA3 148M risk allele(s).
OTHERPlacebo
Participants randomised to placebo will receive the corresponding dose volume of solution as participants receiving AZD2693 within the same cohort
Sponsors
Parexel
AstraZeneca
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Masking description
The study will be blinded for all study site personal including the principal investigator during the clinical conduct of a given cohort. Investigators will remain blinded to each participant's assigned study intervention throughout the course of the study.
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
For Cohorts 1 to 3: * An MRI-PDFF ≥7% and one of the following: * Previous liver biopsy: Acceptable if taken in the previous 3 years for fibrosis stages F0 to F2, or within the previous 1 year for stage F3; or * Previous imaging results taken in the previous 2 years: An MRE between 2.55 kPa and 3.63 kPa, or a vibration-controlled transient elastography (VCTE) between 7.1 kPa and 11.9 kPa; * Participants who are homozygous for rs738409 (PNPLA3 148M). Cohort 2 will enroll participants who are heterozygous for PNPLA3 148M. For Cohort 4: • An MRI-PDFF ≥ 7% and participant's consent for a liver biopsy. * Participants with suspected or confirmed Non-alcoholic fatty liver disease (NAFLD) or NASH are eligible for the Screening liver biopsy if they meet main protocol inclusion/
Exclusion criteria
AND have any of the following: Alanine aminotransferase \> Upper Limit of Normal (ULN) but \< 3 × ULN, OR Imaging demonstrating hepatic steatosis including attenuation parameter (CAP) \> 290dB/m, OR A Magnetic resonance elastography (MRE) between 2.55 kPa and 3.63 kPa, or a vibration-controlled transient elastography (VCTE) between 7.1 kPa and 11.9 kPa. * Histologic evidence of NAFLD or NASH with a NASH Activity Score (NAS) ≥ 3 (independent of subcategory scoring) following Screening liver biopsy. * Participants who are homozygous for rs738409 (PNPLA3 148M).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of participants with adverse events | Up to 32 weeks (From Screening to Final Visit) |
Secondary
| Measure | Time frame |
|---|---|
| Absolute change from baseline in disease-specific biomarkers | Days 1, 8, 29, 36, 50, 64, and 78 |
| Percentage change from baseline in disease-specific biomarkers | Days 1, 8, 29, 36, 50, 64, and 78 |
| Accumulation ratio based on AUC (RacAUC) | Day 1 to Day 162 |
| Temporal change parameter in systemic exposure (TCP) | Day 1 to Day 162 |
| Absolute change from baseline in Gamma Glutamyl Transferase | Up to 32 weeks (From Pre-Screening to Final Visit) |
| Percent change from baseline in Gamma Glutamyl Transferase | Up to 32 weeks (From Pre-Screening to Final Visit) |
| Absolute change from baseline in Enhanced Liver Fibrosis (ELF) score | Up to 32 weeks (From Pre-Screening to Final Visit) |
| Percent change from baseline in ELF score | Up to 32 weeks (From Pre-Screening to Final Visit) |
| Absolute change from baseline in plasma pharmacodynamic biomarker | Days 1, 8, 29, 36, 50, 64, and 78 |
| Percent change from baseline in Aspartate Aminotransferase | Up to 32 weeks (From Pre-Screening to Final Visit) |
| Absolute change from baseline to Week 8 and Week 12 in liver fat content (LFC) | Baseline (Day 1), Week 8, Week 12 |
| Percent change from baseline to Week 8 and Week 12 in liver fat content (LFC) | Baseline (Day 1), Week 8, Week 12 |
| Absolute change from baseline in Alanine Aminotransferase | Up to 32 weeks (From Pre-Screening to Final Visit) |
| Percent change from baseline in Alanine Aminotransferase | Up to 32 weeks (From Pre-Screening to Final Visit) |
| Absolute change from baseline in Aspartate Aminotransferase | Up to 32 weeks (From Pre-Screening to Final Visit) |
| Absolute change from baseline β-Hydroxybutyrate and lipid profile | Days 1, 8, 29, 36, 50, 64, and 78 |
| Percent change from baseline β-Hydroxybutyrate and lipid profile | Days 1, 8, 29, 36, 50, 64, and 78 |
| Maximum observed plasma drug concentration (Cmax) | Day 1 to Day 162 |
| Time to reach maximum observed plasma concentration (tmax) | Day 1 to Day 162 |
| Terminal elimination rate constant, estimated by log-linear least-squares regression of the terminal part of the concentration-time curve (λz) | Day 1 to Day 162 |
| Apparent terminal elimination half-life associated with the terminal slope (λz) of the semi-logarithmic concentration-time curve, estimated as (ln2)/λz (t½λz) | Day 1 to Day 162 |
| Area under the plasma concentration-time curve from time zero to 48 hours after dosing (AUC(0-48h)) | Day 1 to Day 162 |
| Area under the plasma concentration-curve from time zero to the time of last quantifiable analyte concentration (AUClast) | Day 1 to Day 162 |
| Area under the concentration-time curve from time zero extrapolated to infinity. AUC is estimated by AUClast + Clast/λz where Clast is the last observed quantifiable concentration (AUC) | Day 1 to Day 162 |
| Apparent total body clearance of drug from plasma after extravascular administration calculated as Dose/AUC (CL/F) | Day 1 to Day 162 |
| Mean residence time (MRT) | Day 1 to Day 162 |
| Time delay between drug administration and the first observed concentration in plasma (tlag) | Day 1 to Day 162 |
| Apparent volume of distribution for parent drug at terminal phase (extravascular administration), estimated by dividing the apparent clearance (CL/F) by λz (Vz/F) | Day 1 to Day 162 |
| Area under the plasma concentration-time curve from time zero to time of last quantifiable analyte concentration divided by the dose administered (AUClast/D) | Day 1 to Day 162 |
| Area under the plasma concentration-time curve from time zero extrapolated to infinity divided by the dose administered (AUC/D) | Day 1 to Day 162 |
| Observed maximum plasma concentration divided by the dose administered (Cmax/D) | Day 1 to Day 162 |
| Time of the last quantifiable concentration (tlast) | Day 1 to Day 162 |
| Maximum observed plasma drug concentration at steady state (Cssmax) | Day 1 to Day 162 |
| Minimum observed drug concentration at steady state (Cssmin) | Day 1 to Day 162 |
| Time to reach maximum observed plasma concentration at steady state (tssmax) | Day 1 to Day 162 |
| Area under the concentration-time curve in the dose interval (AUCss) | Day 1 to Day 162 |
| Apparent total body clearance of drug from plasma after extravascular administration calculated as Dose/AUCss (CLss/F) | Day 1 to Day 162 |
| Area under the plasma concentration-time curve from time zero extrapolated to infinity divided by the dose administered (AUCss/D) | Day 1 to Day 162 |
| Observed maximum plasma concentration divided by the dose administered (Cssmax/D) | Day 1 to Day 162 |
| Accumulation ratio based on Cmax (RacCmax) | Day 1 to Day 162 |
| Amount of analyte excreted into the urine from time t1 to t2 (Ae(t1-t2)) | Day 1 and Day 57: Pre-dose and between 0-6 hours, 6-12 hours, 12-24 hours, 24-36 hours and 36-48 hours post-dose |
| Percent change from baseline in plasma pharmacodynamic biomarker | Days 1, 8, 29, 36, 50, 64, and 78 |
| Fraction of dose excreted unchanged into the urine from time t1 to t2 (fe(t1-t2)) | Day 1 and Day 57: Pre-dose and between 0-6 hours, 6-12 hours, 12-24 hours, 24-36 hours and 36-48 hours post-dose |
| Cumulative fraction (%) of dose excreted unchanged into the urine from time zero to the last measured time point (fe(0-last)) | Day 1 and Day 57: Pre-dose and between 0-6 hours, 6-12 hours, 12-24 hours, 24-36 hours and 36-48 hours post-dose |
| Renal clearance of drug from plasma, estimated by dividing Ae(0-t) by AUC(0-t) where the 0-t interval is the same for both Ae and AUC (CLR) | Day 1 and Day 57: Pre-dose and between 0-6 hours, 6-12 hours, 12-24 hours, 24-36 hours and 36-48 hours post-dose |
| Change from placebo to Week 10 in PNPLA3 messenger ribonucleic acid (mRNA) and protein expression (Cohort 4 only) | Week 10 |
| Change from baseline to Week 10 in PNPLA3 mRNA and protein expression (Cohort 4 only) | Baseline, Week 10 |
| Cumulative amount of analyte excreted from time zero through the last sampling interval (Ae(0-last)) | Day 1 and Day 57: Pre-dose and between 0-6 hours, 6-12 hours, 12-24 hours, 24-36 hours and 36-48 hours post-dose |
Countries
United States
Outcome results
None listed